Is brigatinib/brigatinib effective in treating lung cancer?

In first-line treatment, Brigatinib/Brigatinibhas shown significant efficacy compared with traditional chemotherapy drugs (such as platinum compounds) in ALKfusion-positive NSCLC patients. The ALTA-1L study is a clinical trial on the first-line treatment of brigatinib/brigatinib. The results show that it is more effective than crizotinib (Crizotinib ), brigatinib/brigatinib can provide longer progression-free survival (PFS) and overall survival (OS). The study also found that brigatinib also showed good control effects in patients with positive brain metastases.